CAJ | 학술논문

目的：评估 DC-CIK 细胞免疫治疗联合分子靶向药物治疗转移性胃肠恶性肿瘤的临床应用价值。方法随机将60例胃肠恶性肿瘤分为 DC-CIK、靶向加化疗组（联合组 A，20例）、靶向加化疗组（联合组 B，20例）和单纯化疗组（对照组，20例）。抽取患者静脉血50ml，行 DC-CIK 培养，14天后，对联合组 A 患者进行输注。观察治疗前后瘤体变化、体质量变化、K arnofsky 评分等。用 K arno fsky 评分及体质量的改变评价生存质量。结果对照组患者完全缓解( CR )2例,部分缓解( PR )3例,好转( MR )8例,稳定( SD )3例,无改变( PD )4例,总有效率( CR + PR )为25.0%。联合组 B完全缓解( CR )3例,部分缓解( PR )7例,好转(M R )7例,稳定( SD )2例,无改变( PD )1例,总有效率( CR +PR )为50.0%。联合组 A 完全缓解( CR )5例,部分缓解( PR )8例,好转(M R )5例,稳定( SD )2例。总有效率( CR +PR )为65.0%。三组之间总有效率比较差异有统计学意义(P <0.01)。单纯化疗后 K arno fsky 评分平均提高9分,其中提高5例,稳定7例,下降8例,提高率为25.0%；联合组 B 治疗后 K arno fsky 评分平均提高10～15分,其中提高10例,稳定5例,下降5例,提高率为50.0%；联合组 A 治疗后 K arno fsky 评分平均提高15～20分,其中提高15例,稳定3例,下降2例,提高率为75.0%。高于联合组 B(P >0.05)和单纯化疗组(P >0.01)。结论 DC-CIK 联合靶向药物和化疗治疗转移性胃肠恶性肿瘤，瘤体变化总有效率和生存质量明显提高。
목적：평고 DC-CIK 세포면역치료연합분자파향약물치료전이성위장악성종류적림상응용개치。방법수궤장60례위장악성종류분위 DC-CIK、파향가화료조（연합조 A，20례）、파향가화료조（연합조 B，20례）화단순화료조（대조조，20례）。추취환자정맥혈50ml，행 DC-CIK 배양，14천후，대연합조 A 환자진행수주。관찰치료전후류체변화、체질량변화、K arnofsky 평분등。용 K arno fsky 평분급체질량적개변평개생존질량。결과대조조환자완전완해( CR )2례,부분완해( PR )3례,호전( MR )8례,은정( SD )3례,무개변( PD )4례,총유효솔( CR + PR )위25.0%。연합조 B완전완해( CR )3례,부분완해( PR )7례,호전(M R )7례,은정( SD )2례,무개변( PD )1례,총유효솔( CR +PR )위50.0%。연합조 A 완전완해( CR )5례,부분완해( PR )8례,호전(M R )5례,은정( SD )2례。총유효솔( CR +PR )위65.0%。삼조지간총유효솔비교차이유통계학의의(P <0.01)。단순화료후 K arno fsky 평분평균제고9분,기중제고5례,은정7례,하강8례,제고솔위25.0%；연합조 B 치료후 K arno fsky 평분평균제고10～15분,기중제고10례,은정5례,하강5례,제고솔위50.0%；연합조 A 치료후 K arno fsky 평분평균제고15～20분,기중제고15례,은정3례,하강2례,제고솔위75.0%。고우연합조 B(P >0.05)화단순화료조(P >0.01)。결론 DC-CIK 연합파향약물화화료치료전이성위장악성종류，류체변화총유효솔화생존질량명현제고。
Objective To estimate the clinical value of DC-CIK cell immune therapy combined with molecular targeted therapy for metastatic malignant gastrointestinal tumor. Methods 60 cases of gastrointestinal tumor were divided into DC-CIK, targeting plus chemotherapy group (20 cases of group A,), targeting plus chemotherapy group (group B, 20 cases) and chemotherapy only group (control group, 20 cases). Venous blood of patients with 50 ml were extracted, and DC-CIK cell were cultured fort14 days later, and the group A were treated with DC-CIK infusion. Changes of before and after tumor treatment were observed, and body weight changes, Karnofsky score, simultaneous recording of survival. to assess the survival quality improvement were evaluated by score and physical volume with K Arno fsky change. Results There was complete remission (CR) in 2 cases, partial remission (PR) in 3 cases,improvement in 8 cases (MR), stable (SD) in 3 cases, no change (PD) in 4 cases in control group,and the total effective rate(CR + PR) was 25%.There was complete remission (CR) in 2 cases, partial remission (PR) in 3 cases,improvement in 8 cases (MR), stable (SD) in 3 cases, no change (PD) in 4 cases in control group,and the total effective rate(CR + PR) was 25%. There was complete remission (CR) in 3 cases, partial remission (PR) in 7 cases,improvement in7 cases (MR), stable (SD) in 23 cases, no change (PD) in 1 cases in the combined group B,and the total effective rate(CR + PR) was 50%.There was complete remission (CR) in 5 cases, partial remission (PR) in 8 cases,improvement in 5 cases (MR), stable (SD) in 2 cases in combined group A,and the total effective rate(CR + PR) was 65%. Conclusion DC-CIK cell therapy could enhance the effects of anti-cancer, which probably provide a potent immune therapeutic strategy for patients with metastatic malignant gastrointestinal tumor.